Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder.

导出 LinkOut

翻译打印收藏纠错

作者： Evanguelos,Xylinas ^[1] ; Luis A,Kluth ^[1] ; Yair,Lotan ^[2] ; Siamak,Daneshmand ^[3] ; Malte,Rieken ^[1] ; Pierre I,Karakiewicz ^[4] ; Shahrokh F,Shariat ^[5]

作者单位： Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY. ^[1] Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. ^[2] USC Institute of Urology, Norris Comprehensive Cancer Center, Los Angeles, CA. ^[3] Department of Urology, University of Montreal Health Center, Montreal, Canada. ^[4] Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Division of Medical Oncology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: sfshariat@gmail.com. ^[5]

关键词 Biomarker Bladder cancer Blood-based Molecular marker Prediction Prognosis Survival Tissue-based Urothelial carcinoma

主题词癌, 移行细胞(Carcinoma, Transitional Cell);人类(Humans);预后(Prognosis);治疗结果(Treatment Outcome);膀胱肿瘤(Urinary Bladder Neoplasms)

DOI 10.1016/j.urolonc.2013.06.009

PMID 24332648

发布时间 2022-03-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交